Clinical trial NCT02173080: Development and Assessment of The Polycystic Liver Disease Questionnaire (PLD-Q).
Official title: Development and Assessment of the Psychometric Properties of a Polycystic Liver Disease-specific Patient Reported Outcomes Questionnaire (PLD-Q).
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Polycystic Liver Disease
Keywords: autosomal dominant polycystic liver disease
autosomal dominant polycystic kidney disease
quality of life
patient reported outcome tool
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2014-06-24
Enrollment: 594
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with polycystic liver disease

Brief summary: This Pilot study will enable development \& assessment of a Polycystic Liver Disease-specific patient reported outcomes questionnaire (PLD-Q). Polycystic liver disease (PLD) is characterized by the formation of numerous cysts in the liver, and can lead to severe symptomatic hepatomegaly. It is common in patients with autosomal dominant polycystic liver disease (ADPLD) and autosomal dominant polycystic kidney disease (ADPKD).

Detailed description: As liver function is preserved, quality of life is the main outcome in PLD. Patient reported outcomes are increasingly utilized to assess treatment efficacy \& can include any endpoint derived from patient reports \& are usually assessed by questionnaire. Several existing generic questionnaires assess gastrointestinal symptoms, but include irrelevant items for polycystic liver disease (PLD) \& do not examine relevant extra-abdominal symptoms. Also, a questionnaire that assesses the full range of PLD related problems is more likely to be responsive to changes after treatment initiation. Therefore, a tool that accurately detects changes in PLD symptoms is required.

The development and first steps of validation of this questionnaire are already completed in Netherlands. We will further develop this questionnaire for English speaking patients and validate it in Mayo Clinic cohorts.

The study contains three phases. Phase 1: pilot testing of the directly translated questionnaire (from dutch into english) in a small group of polycystic liver disease (PLD) patients. We will include both symptomatic \& asymptomatic patients (i.e. from mild to severe PLD). Phase 2: further refinement of the questionnaire using the results of the pilot test and input of Mayo patient and clinician focus groups. Phase 3: Further validation in a large cohort of 200 PLD patients with (1) comparison with 200 controls without PLD, (2) cross-sectional correlation with total liver (TLV) \& kidney volumes (TKV), (3) comparing ADPKD patients with \& without PLD (5) against other validated questionnaires (e.g. SF36) \& (5) development of a custom "Worry Questionnaire" examining disease-related worries \& concerns. Finally, longitudinal analyses will be performed to assess PLD-Q sensitivity to change in symptoms. Statistical \& psychometric analyses will be provided by Mayo Clinic quality of life Research group, \& developed in accordance with Food and Drug Administration (FDA) guidance on patient-reported outcome measures in consultation with their Study Endpoints \& Labeling Development Division.

Eligibility criteria: Inclusion Criteria:

* Patients ≥ 18 year
* Polycystic liver, defined by \> 20 liver cysts on imaging

Exclusion Criteria:

* Patients unable to speak or read the English properly
* History of kidney or liver transplantation
* Dialysis
* Current use of experimental drugs (e.g. lanreotide, octreotide)
* Recent liver resection or major surgery
* Other comorbidities that can affect the outcome of the questionnaire, as deemed by the investigators

Primary outcomes:
measure: Polycystic Liver Disease-specific patient reported outcomes questionnaire (PLD-Q) total score
timeFrame: baseline to 6 months
Secondary outcomes:
measure: The Short Form (36) Health Survey (SF36)
timeFrame: baseline to 6 months
measure: European Organisation for Research and Treatment of Cancer Quality of life questionnaire (EORTC-QLQ-C30) symptom subscale
timeFrame: baseline to 6 months
measure: Euroqol group 5 dimensions questionnaire visual analog score (EQ5D-VAS)
timeFrame: baseline to 6 months
measure: Total liver volume
timeFrame: baseline
measure: Total kidney volume
timeFrame: baseline
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Marie C Hogan
role: PRINCIPAL_INVESTIGATOR
References: